General Information
Version
7.1
Revision date
2025-11-03
Product name
Clonazepam impurity B
CAS No.
55198-89-5
Emergency telephone
800-789-767, +39-02-4555-7031, +39 02-6610-1029
Icons in SDS
Company Information
company name
Merck Life Science S.r.l
e-mail address of the competent person responsible for the Safety Data Sheet
serviziotecnico@merckgroup.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H336, H412
Hazard statements
Code
Statements
H336
May cause drowsiness or dizziness
Section 2
SECTION 2: Hazards identification
2.1 Classification of the substance or mixture
Specific target organ toxicity - H336: May cause drowsiness or dizziness. single exposure, (Category 3), Central nervous system Long-term (chronic) aquatic H412: Harmful to aquatic life with long hazard, (Category 3) lasting effects.
Signal word
Warning Warning
Hazard statements
H336 May cause drowsiness or dizziness. H412 Harmful to aquatic life with long lasting effects. H412 Harmful to aquatic life with long lasting effects.
Precautionary statements
P261 Avoid breathing dust. P271 Use only outdoors or in a well-ventilated area. P273 Avoid release to the environment. P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell. P403 + P233 Store in a well-ventilated place. Keep container tightly closed. P405 Store locked up. none
Supplemental label elements
none Reduced Labelling (<= 125 ml) none
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
